Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate

NCT00254267 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00254267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00254267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
December 31, 2012
Enrollment
35 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal stromal tumor